ML-098
Selleck Chemicals
SKU:E2389-5MG
Couldn't load pickup availability

ML-098 is annotated as an activator in this dataset and is relevant to cancer and cell cycle models. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to compound-linked biochemical, transcriptional, and phenotypic responses in cancer and cell cycle models.
Because the current annotation identifies ML-098 as an activator, it is suited to comparative profiling, concentration-response work, and follow-up studies that track compound-dependent signaling or phenotype changes without assuming a single assigned primary target. That positioning is consistent with gain-of-function pathway-activation studies and with follow-up studies that compare concentration-dependent responses across orthogonal assay formats. In cancer and cell cycle models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.
Research Applications
- Gain-of-function pathway-activation studies
- Phenotypic profiling in cancer and cell cycle models
- Combination studies with orthogonal perturbagens
- Mechanism-oriented follow-up using biochemical and cellular endpoints
Overall, ML-098 is appropriate for mechanism-oriented studies that require an activator-annotated compound for comparative profiling in cancer and cell cycle models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.
- Research Area:
- Cancer • Cell Cycle
- CAS No.:
- 878978-76-8
- Molecular Weight:
- 309.36
- Formula:
- C₁₉H₁₉NO₃
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.